Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Paloma Sosa‐Fajardo
Observed names:
Paloma Sosa Fajardo,
Paloma Sosa-Fajardo,
Sosa Fajardo, Paloma
Institutions:
Hospital Universitario Virgen del Rocío,
Servicio Gallego de Salud
Observed institutions:
Complejo Hospitalario Universitario de Santiago,
Fundación Pública Galega de Medicina Xenómica,
Instituto de Biomedicina de Sevilla,
Instituto de Investigación Sanitaria de Santiago,
Hospital Universitario Virgen del Rocío,
Servicio Gallego de Salud,
Universidad de Sevilla
show all 7
ORCID:
0000-0002-0130-321X
Observed ORCID:
0000-0002-0130-321X
OpenAlex ID:
A5010185548
REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer
2019
·
Petra Seibold
, Adam Webb
, et al.
·
Radiotherapy and Oncology
·
112
PDF
Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity
2021
·
Nicola Rares Franco
, Michela Carlotta Massi
, et al.
·
Radiotherapy and Oncology
·
34
PDF
Treatment time and circadian genotype interact to influence radiotherapy side-effects. A prospective European validation study using the REQUITE cohort
2022
·
Adam J. Webb
, Emily Harper
, et al.
·
EBioMedicine
·
30
PDF
Large-scale meta–genome-wide association study reveals common genetic factors linked to radiation-induced acute toxicities across cancer types
2023
·
Elnaz Naderi
, Miguel E Aguado-Barrera
, et al.
·
JNCI Cancer Spectrum
·
24
PDF
Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer
2022
·
Sarah L. Kerns
, Ashley Amidon Morlang
, et al.
·
Radiotherapy and Oncology
·
23
PDF
The correlation between pre-treatment symptoms, acute and late toxicity and patient-reported health-related quality of life in non-small cell lung cancer patients: Results of the REQUITE study
2022
·
Lotte van der Weijst
, David Azria
, et al.
·
Radiotherapy and Oncology
·
18
Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study)
2022
·
Lotte Van der Weijst
, Miguel E. Aguado-Barrera
, et al.
·
Lung Cancer
·
15
PDF
Radiogenomics in lung cancer: Where are we?
2023
·
Miguel E. Aguado-Barrera
, Paloma Sosa-Fajardo
, et al.
·
Lung Cancer
·
13
No Association Between Polygenic Risk Scores for Cancer and Development of Radiation Therapy Toxicity
2022
·
Gillian C. Barnett
, Sarah L. Kerns
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
·
7
PDF
Advances and controversies in the management of early stage non-small cell lung cancer
2021
·
Angel Cilleruelo-Ramos
, Esther Cladellas-Gutiérrez
, et al.
·
World Journal of Clinical Oncology
·
7
Stereotactic body radiation therapy for kidney cancer. Where do we stand?
2023
·
Paloma Sosa‐Fajardo
, Jesús M. Blanco‐Suarez
, et al.
·
International Journal of Urology
·
6
PDF
Facial Donor Restoration: One-Step Technique
2019
·
Hector Hurtado-Ruzza
, Paloma Sosa-Fajardo
, et al.
·
Journal of Oral and Maxillofacial Surgery
·
3
Long-term fatigue dimensions in the Multidimensional Fatigue Inventory (MFI) up to five years after radiotherapy and their trajectories in men diagnosed with non-metastatic prostate cancer in the international REQUITE study
2026
·
Philipp Heumann
, Juan C. Rosas
, et al.
·
British Journal of Cancer
PDF
Long-term fatigue based on the EORTC QLQ-C30 up to five years after radiotherapy and its trajectories in men diagnosed with non-metastatic prostate cancer in the international REQUITE study
2026
·
Philipp Heumann
, Juan C. Rosas
, et al.
·
British Journal of Cancer
PDF
Data from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
2026
·
Adam J. Webb
, Emily Harper
, et al.
Table 4 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
2026
·
Adam J. Webb
, Emily Harper
, et al.
Table 3 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
2026
·
Adam J. Webb
, Emily Harper
, et al.
Supplementary Table S1 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
2026
·
Adam J. Webb
, Emily Harper
, et al.
Supplementary Appendix S1 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
2026
·
Adam J. Webb
, Emily Harper
, et al.
Figure 2 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
2026
·
Adam J. Webb
, Emily Harper
, et al.
Supplementary Table S2 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
2026
·
Adam J. Webb
, Emily Harper
, et al.
Table 2 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
2026
·
Adam J. Webb
, Emily Harper
, et al.
Supplementary Table S3 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
2026
·
Adam J. Webb
, Emily Harper
, et al.
Supplementary Table S4 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
2026
·
Adam J. Webb
, Emily Harper
, et al.
Table 1 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
2026
·
Adam J. Webb
, Emily Harper
, et al.
Show more works
View as search
Works count:
37
Citation count:
292
H-index:
8
I10-index:
8
Year
Topic
Type